What Happened:
In a recent readiness briefing, DCI Consulting Principal Consultant Murray Simpson, Ph.D., told total rewards leaders to "be ready to satisfy pay transparency obligations by the June 7, 2026, transposition deadline" regardless of where their member state's law lands. TSlovakia became the first member state to fully transpose the directive, and on May 22 the European Commission confirmed it will not delay, extend, or fold the rules into an omnibus simplification package.
Only Slovakia and Italy have full implementing legislation in force, the Netherlands and Denmark have already announced they will miss the deadline and target January 1, 2027, and Sweden has paused entirely and called for renegotiation, according to L&E Global's late-May tracker.
From June 7, the directive's substantive obligations start to bind, including recruitment salary disclosure, the workers' right to pay info, the ban on pay-secrecy clauses, and the shifted burden of proof in pay discrimination cases.
More Insight:
The widening ratio is mostly an equity story. Median total direct comp ticked up 4.3% year over year, but the 25th and 75th percentiles climbed 7% and 8.3%, which tracks with strong public equity valuations carrying long-dated stock grants higher across the curve. The Harvard recap argues the gap will keep widening for as long as equity sits at the center of the package and the market cooperates. The SEC's pay-versus-performance disclosure rule, now in its fourth proxy cycle, makes the comparison easier for activists and proxy advisors to attack, and that visibility is showing up in the close votes.
What the say-on-pay vote tells comp leaders is the structural story. Support held above the three-year average, and the failure count came in at roughly half of recent seasons. Investors are signaling tolerance for magnitude. The failures cluster on two complaints, weak linkage between pay and performance, and short time horizons on the incentive side.
The three large-cap losses make that explicit. IQVIA's package for CEO Ari Bousbib, roughly $28 million, drew 24.8% support, the lowest in the large-cap universe this season. Skyworks Solutions landed at 49.8%. Arrowhead Pharmaceuticals' advisory vote went down 60-40. The board narratives differ, but the investor letters cluster on the same two complaints. A one-time award sized ahead of performance, and a vesting horizon that paid out before the strategy did. ISS and Glass Lewis recommended against all three.
Shareholders are voting on structure. Equity-heavy packages will survive when the metrics, the vesting cliffs, and the relative TSR story hold up. They will not survive when a special grant lands ahead of results or when the time horizon collapses before the strategy does.